CL2015000891A1 - Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras. - Google Patents
Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.Info
- Publication number
- CL2015000891A1 CL2015000891A1 CL2015000891A CL2015000891A CL2015000891A1 CL 2015000891 A1 CL2015000891 A1 CL 2015000891A1 CL 2015000891 A CL2015000891 A CL 2015000891A CL 2015000891 A CL2015000891 A CL 2015000891A CL 2015000891 A1 CL2015000891 A1 CL 2015000891A1
- Authority
- CL
- Chile
- Prior art keywords
- anxiety
- modulators
- pain
- depression
- phenyl
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title 1
- -1 Phenyl-ethynyl Chemical class 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188940 | 2012-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000891A1 true CL2015000891A1 (es) | 2015-09-11 |
Family
ID=47049067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000891A CL2015000891A1 (es) | 2012-10-18 | 2015-04-09 | Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9227959B2 (enExample) |
| EP (1) | EP2909180B1 (enExample) |
| JP (1) | JP5989250B2 (enExample) |
| KR (1) | KR101684816B1 (enExample) |
| CN (1) | CN104718192B (enExample) |
| AR (1) | AR093042A1 (enExample) |
| AU (1) | AU2013333988B2 (enExample) |
| BR (1) | BR112015006454A8 (enExample) |
| CA (1) | CA2882520A1 (enExample) |
| CL (1) | CL2015000891A1 (enExample) |
| CO (1) | CO7200248A2 (enExample) |
| CR (1) | CR20150144A (enExample) |
| EA (1) | EA025667B1 (enExample) |
| ES (1) | ES2599553T3 (enExample) |
| IL (1) | IL237380A (enExample) |
| MA (1) | MA38012B1 (enExample) |
| MX (1) | MX2015004898A (enExample) |
| MY (1) | MY168937A (enExample) |
| NZ (1) | NZ705144A (enExample) |
| PE (1) | PE20150629A1 (enExample) |
| PH (1) | PH12015500398A1 (enExample) |
| SG (1) | SG11201501392TA (enExample) |
| TW (1) | TWI490208B (enExample) |
| UA (1) | UA114529C2 (enExample) |
| WO (1) | WO2014060398A1 (enExample) |
| ZA (1) | ZA201500856B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA114008C2 (xx) * | 2012-10-18 | 2017-04-10 | Похідні етинілу як модулятори активності рецептора mglur5 | |
| AU2016273751B2 (en) * | 2015-06-03 | 2020-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| EP3353161B1 (en) * | 2015-09-25 | 2021-07-21 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Triazole derivatives as p2y14 receptor antagonists |
| RS62517B1 (sr) | 2017-12-08 | 2021-11-30 | Boehringer Ingelheim Int | Derivati imidazopiridina i njihova upotreba kao leka |
| EA202191014A1 (ru) * | 2018-10-17 | 2021-11-09 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства |
| TW202035396A (zh) | 2018-10-17 | 2020-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 4-吡啶基甲基-嗎啉衍生物及其作為藥物之用途 |
| CN112888684B (zh) * | 2018-10-17 | 2023-10-10 | 勃林格殷格翰国际有限公司 | 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途 |
| US12398143B2 (en) | 2019-06-04 | 2025-08-26 | Boehringer Ingelheim International Gmbh | Imidazopyrazine derivatives and the use thereof as medicament |
| WO2020245136A1 (en) | 2019-06-04 | 2020-12-10 | Boehringer Ingelheim International Gmbh | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| KR20100033981A (ko) * | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
| US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| WO2013049255A1 (en) * | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
-
2013
- 2013-10-15 MY MYPI2015000470A patent/MY168937A/en unknown
- 2013-10-15 PE PE2015000396A patent/PE20150629A1/es active IP Right Grant
- 2013-10-15 JP JP2015535066A patent/JP5989250B2/ja not_active Expired - Fee Related
- 2013-10-15 BR BR112015006454A patent/BR112015006454A8/pt not_active Application Discontinuation
- 2013-10-15 EA EA201590699A patent/EA025667B1/ru not_active IP Right Cessation
- 2013-10-15 CN CN201380053660.XA patent/CN104718192B/zh not_active Expired - Fee Related
- 2013-10-15 SG SG11201501392TA patent/SG11201501392TA/en unknown
- 2013-10-15 WO PCT/EP2013/071500 patent/WO2014060398A1/en not_active Ceased
- 2013-10-15 NZ NZ705144A patent/NZ705144A/en not_active IP Right Cessation
- 2013-10-15 AU AU2013333988A patent/AU2013333988B2/en not_active Ceased
- 2013-10-15 CA CA2882520A patent/CA2882520A1/en not_active Abandoned
- 2013-10-15 MX MX2015004898A patent/MX2015004898A/es unknown
- 2013-10-15 EP EP13783003.0A patent/EP2909180B1/en active Active
- 2013-10-15 KR KR1020157009544A patent/KR101684816B1/ko not_active Expired - Fee Related
- 2013-10-15 ES ES13783003.0T patent/ES2599553T3/es active Active
- 2013-10-15 UA UAA201504680A patent/UA114529C2/uk unknown
- 2013-10-17 AR ARP130103764A patent/AR093042A1/es unknown
- 2013-10-17 TW TW102137560A patent/TWI490208B/zh not_active IP Right Cessation
-
2015
- 2015-02-05 ZA ZA2015/00856A patent/ZA201500856B/en unknown
- 2015-02-16 CO CO15032736A patent/CO7200248A2/es unknown
- 2015-02-23 IL IL237380A patent/IL237380A/en not_active IP Right Cessation
- 2015-02-24 PH PH12015500398A patent/PH12015500398A1/en unknown
- 2015-03-18 CR CR20150144A patent/CR20150144A/es unknown
- 2015-04-09 CL CL2015000891A patent/CL2015000891A1/es unknown
- 2015-04-17 MA MA38012A patent/MA38012B1/fr unknown
- 2015-04-17 US US14/689,375 patent/US9227959B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
| BR112014021103A8 (pt) | anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2014001280A1 (es) | Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| LT3216448T (lt) | Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. | |
| CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. | |
| CL2015001233A1 (es) | Compuestos heteroaromáticos fusionados; composicion farmaceutica y el uso como ligandos d1 de dopamina en el tratamiento de enfermedades tales como esquizofrenia. |